CellCentric

Private

Cambridge, UK clinical-stage biotech developing inobrodib, a first-in-class oral p300/CBP inhibitor for relapsed/refractory multiple myeloma and other cancers. Based on the science of Azim Surani at the Gurdon Institute, Cambridge.

Founders Will West

CEO Will West

Company

Founded

2007

Headquarters

Cambridge, United Kingdom

Financials

Total Funding

$340M

Sectors

Healthtech Biotech

www.cellcentric.com

Funding History

2 rounds

Series D May 7, 2026

$220M

Venrock Healthcare Capital Partners (Lead) Fidelity Management & Research Sofinnova Partners HBM Healthcare RA Capital Management Forbion Pfizer Ventures Avego BioScience Capital ACS BrightEdge

Series C Sep 15, 2024

$120M

Funding data is compiled from multiple independent sources including company announcements, press coverage, and regulatory filings. While we strive for accuracy, amounts and dates may reflect reported figures at time of announcement.